{"title":"炎症性神经病变的生物标志物:进展如何?","authors":"Milou R Michael, Luuk Wieske, Filip Eftimov","doi":"10.1097/WCO.0000000000001406","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose of review: </strong>This review provides an overview of recent advances in fluid-based biomarker research in inflammatory neuropathies, with a particular focus on disease activity monitoring. It explores challenges along the biomarker pipeline and outlines the stage of development of emerging disease activity biomarkers.</p><p><strong>Recent findings: </strong>Numerous biomarkers have recently been investigated for diagnostic, prognostic and monitoring purposes. Neurofilament light chain has been studied furthest but its clinical utility is limited in most patients. Other recent work has identified new biomarkers reflecting nerve damage, including peripherin, periaxin and Contactin-1. Additionally, potential immunological markers of disease activity have been explored, some more generic (such as chemokines) and others highly disease specific (such as autoantibody titers). Additional candidates have emerged through unbiased high-throughput discovery studies.</p><p><strong>Summary: </strong>Current fluid-based biomarkers can be grouped into nerve damage or immunological biomarkers. Most have not proceeded beyond discovery and validation stages, except for Neurofilament Light Chain. Biomarker development is challenging due to the inherent rarity and heterogeneity of inflammatory neuropathies, and, in the case of disease activity biomarkers, a lack of reference standard.</p>","PeriodicalId":11059,"journal":{"name":"Current Opinion in Neurology","volume":" ","pages":"459-470"},"PeriodicalIF":4.4000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Biomarkers in inflammatory neuropathies: where are we?\",\"authors\":\"Milou R Michael, Luuk Wieske, Filip Eftimov\",\"doi\":\"10.1097/WCO.0000000000001406\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose of review: </strong>This review provides an overview of recent advances in fluid-based biomarker research in inflammatory neuropathies, with a particular focus on disease activity monitoring. It explores challenges along the biomarker pipeline and outlines the stage of development of emerging disease activity biomarkers.</p><p><strong>Recent findings: </strong>Numerous biomarkers have recently been investigated for diagnostic, prognostic and monitoring purposes. Neurofilament light chain has been studied furthest but its clinical utility is limited in most patients. Other recent work has identified new biomarkers reflecting nerve damage, including peripherin, periaxin and Contactin-1. Additionally, potential immunological markers of disease activity have been explored, some more generic (such as chemokines) and others highly disease specific (such as autoantibody titers). Additional candidates have emerged through unbiased high-throughput discovery studies.</p><p><strong>Summary: </strong>Current fluid-based biomarkers can be grouped into nerve damage or immunological biomarkers. Most have not proceeded beyond discovery and validation stages, except for Neurofilament Light Chain. Biomarker development is challenging due to the inherent rarity and heterogeneity of inflammatory neuropathies, and, in the case of disease activity biomarkers, a lack of reference standard.</p>\",\"PeriodicalId\":11059,\"journal\":{\"name\":\"Current Opinion in Neurology\",\"volume\":\" \",\"pages\":\"459-470\"},\"PeriodicalIF\":4.4000,\"publicationDate\":\"2025-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Opinion in Neurology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/WCO.0000000000001406\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/6/12 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Neurology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/WCO.0000000000001406","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/12 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
Biomarkers in inflammatory neuropathies: where are we?
Purpose of review: This review provides an overview of recent advances in fluid-based biomarker research in inflammatory neuropathies, with a particular focus on disease activity monitoring. It explores challenges along the biomarker pipeline and outlines the stage of development of emerging disease activity biomarkers.
Recent findings: Numerous biomarkers have recently been investigated for diagnostic, prognostic and monitoring purposes. Neurofilament light chain has been studied furthest but its clinical utility is limited in most patients. Other recent work has identified new biomarkers reflecting nerve damage, including peripherin, periaxin and Contactin-1. Additionally, potential immunological markers of disease activity have been explored, some more generic (such as chemokines) and others highly disease specific (such as autoantibody titers). Additional candidates have emerged through unbiased high-throughput discovery studies.
Summary: Current fluid-based biomarkers can be grouped into nerve damage or immunological biomarkers. Most have not proceeded beyond discovery and validation stages, except for Neurofilament Light Chain. Biomarker development is challenging due to the inherent rarity and heterogeneity of inflammatory neuropathies, and, in the case of disease activity biomarkers, a lack of reference standard.
期刊介绍:
Current Opinion in Neurology is a highly regarded journal offering insightful editorials and on-the-mark invited reviews; covering key subjects such as cerebrovascular disease, developmental disorders, neuroimaging and demyelinating diseases. Published bimonthly, each issue of Current Opinion in Neurology introduces world renowned guest editors and internationally recognized academics within the neurology field, delivering a widespread selection of expert assessments on the latest developments from the most recent literature.